知镜 Cognispect · 医学文献与研究工作台

Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.

Pasnoor M, Miller-Wilson LA, Edwards Y, Copley-Merriman K, Costello J, Foss A, Muppidi S.
Journal of neurology · 2026-04-25 · PMID 42033462

文献摘要

Background Myasthenia gravis (MG) is a rare autoimmune neurologic disorder with a heterogenous disease presentation. The objective of this targeted literature review was to characterize the burden of disease and unmet treatment needs in patients with MG. Methods Scientific articles published in English between May 4, 2013, and November 24, 2025, were identified in the PubMed, Medline, Embase, and Cochrane Library databases using a pre-defined Boolean search strategy. Titles and abstracts were screened for information on clinical presentation, pathology, and diagnostic considerations for MG; burden of disease, including epidemiologic, clinical, humanistic, and economic burden; and treatments, including treatment guidelines. Results The analysis included 318 records. Population-based estimates of MG incidence published from 2007 onwards ranged from 0.3 to 6.1 per 100,000 person-years, and prevalence estimates ranged from 2.2 to 58.6 per 100,000 persons. The clinical and humanistic burden of MG remains high, with patients reporting inadequate symptom control, fatigue, poor quality of life, and dissatisfaction with their current treatment. Greater disease severity was associated with reduced quality of life and poorer mental health. Medical costs varied by region, and key drivers of direct medical costs include hospitalization and treatment of exacerbation or myasthenic crisis. Conclusion The burden of MG remains high, despite the availability of novel treatments. Studies are needed to better characterize the current burden of MG in the context of newer treatment options and to explore how the disease burden may be reduced for patients.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。